



HAL
open science

Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications.

Chunfu Yang, Chaoyang Deng, Junfeng Wan, Liye Zhu, Qibin Leng

► **To cite this version:**

Chunfu Yang, Chaoyang Deng, Junfeng Wan, Liye Zhu, Qibin Leng. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications.. Virology Journal, 2011, 8, pp.306. 10.1186/1743-422X-8-306 . pasteur-00624836

HAL Id: pasteur-00624836

<https://riip.hal.science/pasteur-00624836v1>

Submitted on 20 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access

Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications

Chunfu Yang¹, Chaoyang Deng¹, Junfeng Wan², Liye Zhu^{2*} and Qibin Leng^{1*}

Abstract

Enterovirus 71 (EV71) has emerged as a significant pathogen causing large outbreaks in China for the past 3 years. Developing an EV71 vaccine is urgently needed to stop the spread of the disease; however, the adaptive immune response of humans to EV71 infection remains unclear. We examined the neutralizing antibody titers in HFMD patients and compared them to those of asymptomatic healthy children and young adults. We found that 80% of HFMD patients became positive for neutralizing antibodies against EV71 (GMT = 24.3) one day after the onset of illness. The antibody titers in the patients peaked two days (GMT = 79.5) after the illness appeared and were comparable to the level of adults (GMT = 45.2). Noticeably, the antibody response was not correlated with disease severity, suggesting that cellular immune response, besides neutralizing antibodies, could play critical role in controlling the outcome of EV71 infection in humans.

Keywords: EV71, neutralizing antibody, hand, foot and mouth disease, cellular immune response, vaccine

Background

Historically, the outbreaks of HFMD (hand, foot and mouth disease) in European countries and the United States have been spontaneous and small in scale. Noticeably, there were also two large outbreaks with high mortality rates in Bulgaria (1975) [1] and Hungary (1978) [2]. In recent years numerous large outbreaks of HFMD have occurred in eastern and southeastern Asian countries and regions, including Malaysia [3], Singapore [4], Taiwan [5], Japan [6], South Korea [7], Vietnam [8] and mainland China [9]. HFMD has become an emerging disease in China since March 2008 [10]. Accumulating cases so far have reached 3.4 million, including nearly 1400 fatalities. It is worth mentioning that not only deaths have increased 156% over the last year, but the overall number of severe cases has also increased significantly. The noticeable difference of these outbreaks in China from other regions is that the

circulating EV71 viruses are only from the C4 genotype [11], but the reasons for causing large outbreaks in China still remains largely unclear. Environmental, human genetic and immunological factors all have, most likely, contributed to it.

In recent years, several EV71 vaccine candidates, including live-attenuated virus, inactivated whole virus, recombinant viral protein, virus-like particle and DNA vaccine, have been evaluated in animal studies [12-17]. The vaccine studies in animal models have demonstrated that neutralizing antibodies may play a critical role in protecting mice from the viral challenge [12,13,16]. EV71 vaccine clinical trials have been approved recently and will be soon carried out in China. Other than the target populations, it is difficult to predict what antibody titer will be considered as a protective level in the clinical trials. Probably the best way to discover this information is to study naturally-occurring EV71 infections in patients.

Because the current outbreak in China began in March 2008 in the city of Fuyang, located in northwestern Anhui province [18], we retrospectively compared the antibody response of patients to EV71 infection in Fuyang to asymptomatic healthy children and young

* Correspondence: fycdjck@163.com; qbleng@sibs.ac.cn

¹Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 225 South Chongqing Road, Shanghai, 200025, P.R. China

²Center for Disease Control of Fuyang city, 19 Zhongnan Avenue, Fuyang City, Anhui Province, 236300, P.R. China

Full list of author information is available at the end of the article

adults. We found that neutralizing antibody titers against EV71 was detectable one day after symptoms manifested and reached peak levels 2 days afterwards. To our surprise, the antibody response was not correlated with severity of the disease. In addition, more than 17% patients had less than a 1:16 neutralizing antibody titer. Thus, our data suggests that the neutralizing antibody may not be the only mechanisms protecting adults as well as children from EV71 infection.

Results

In 2008, there were 7,470 reported cases of HFMD in the city of Fuyang during the period from March 1 to May 31, of which 4840 patients were hospitalized and 23 cases were fatal (case fatality rate = 0.31%). The number of cases, according to date of onset, began to increase in early April and peaked on April 28. The number of reported HFMD cases in Fuyang decreased after May 5. RT-PCR analysis of EV71 nucleic acid revealed that 69 of 161 cases (60.3%) were positive in various specimens, including pharyngeal swabs, lung puncture fluid, lung tissues and blood. All of them were negative in RT-PCR analysis of Coxsackievirus A16 (CA16) nucleic acid. Therefore, EV71 but not CA16 was determined to be the causative pathogen.

In this study, we analyzed 58 HFMD patients and 60 healthy controls. Both groups ranged in age from 1 to 3 years old. Among the patients, 13 of them had typical HFMD symptoms such as a skin rash and fever and were assigned to the mild group. Twenty-eight patients were critical with severe neurological pulmonary edema. Seventeen had less CNS involvement such as poliomyelitis-like syndrome, acute flaccid paralysis, encephalomyelitis, aseptic meningitis or encephalitis.

Similar to previous finding [10], we found that 41.2% of HFMD-asymptomatic healthy children had neutralizing antibody titers of 1:8 or above against EV71 (geometric mean titer, GMT = 7.4). The proportion of the healthy controls that had neutralizing antibody titers \geq 1:16 and \geq 1:64 dropped to 30.6% and 3.4%, respectively, while none of them had \geq 1:128 antibody titers. In contrast, 10 of 12 adults (83.3%) had neutralizing antibody titers \geq 1:16, which were significantly higher (GMT = 45.3) than those of the healthy children. Of note, 4 of 12 adults had neutralizing antibody titers \geq 1:128 (Figure 1A).

Overall HFMD patients had remarkably higher levels of neutralizing antibody titers (GMT = 72) than the healthy controls ($p < 0.01$). The proportion of patients having neutralizing antibody titers \geq 1:8, \geq 1:16, \geq 1:32, \geq 1:64, \geq 1:128, \geq 1:256, \geq 1:512 were 93.2%, 81.3%, 72.9%, 54.2%, 23.7%, 3.4% and 1.7%, respectively. The antibody titers in the patients with CNS involvement or pulmonary edema were not significantly different from those of patients with

mild HFMD [Figure 1B], suggesting that the neutralizing antibody titers were not associated with the severity of the disease.

Because the serum samples were collected at various periods after the appearance of symptoms, we questioned whether the antibody titers were associated with the collection times. Overall, our analysis revealed that the antibody titers were not correlated with the collection times. Noticeably, the serum samples collected one day after the onset of illness had significantly lower levels of neutralizing antibodies than the samples collected at a later time [Figure 2A]. However, the neutralizing antibody titers from the serum samples of patients collected one day after falling ill (GMT = 24.3) were already more than 3 times higher than that of healthy control children (GMT = 7.4) [Figure 2B]. In addition, 4 of 5 patients had neutralizing antibody titers above 1:16. These data suggest that neutralizing antibodies are typically produced when symptoms appear in patients.

Methods and materials

Human subjects and serum samples


The enrollment of HFMD patients was reported by CDC to the WHO previously [18]. Accordingly, all the patients had the following symptoms: 1) skin rash or blisters on hand, foot, or buttock, and fever, in the absence of measles, rubella, chicken pox and other febrile eruption diseases; 2) skin rash or blisters on hand, foot, or buttock, and ulcers on the mouth or mucous membrane, in the absence of drug-related rash or allergy. Severe cases were defined as having two of following clinical manifestations: 1) continuous high fever, 2) weakness, vomiting, irritability, etc., 3) abnormal white blood cell count, 4) high blood glucose level or/and 5) poor blood circulation of limbs. Pulmonary edema was defined as respiratory distress, associated with tachycardia, tachypnea, rales, and copious frothy sputum, with a chest roentgenograph that showed bilateral pulmonary infiltrates without cardiomegaly [19].

Serum samples from control children, adults and HFMD patients were collected by the Center for Disease Control of Fuyang city for the purpose of national HFMD surveillance in 2008 [18]. Written informed consents were obtained for the use of serum samples from all participants (or their parents). This study has been approved by the ethics committee of Center for Disease Control of Fuyang city. The serum samples from the patients whose ages ranged from 1-3 years old were analyzed in this study.

Neutralization assay

The methods for measuring EV71 neutralizing antibodies on microtiter plates have been described previously

A.



B.





Figure 1 Reverse cumulative distribution curves of neutralizing antibody titers in HFMD patients, healthy children and adults subjects by microneutralization assay against EV71. A. HFMD patients were analyzed as one group. B. HFMD patients were further categorized into mild group, severe group without pulmonary edema and severe group with pulmonary edema in accordance with their disease severity.

[20-22]. Briefly, heat-inactivated (56°C for 30 min) sera were serially diluted in two-fold steps in Eagle's minimal essential medium containing 2% fetal bovine serum (MEM-2), with an initial serum dilution of 1:8. The tissue culture infectious dose (TCID₅₀) of the viral stocks was determined and then diluted 10-fold, 10²-fold and 10³-fold with MEM-2. Diluted sera and 100 TCID₅₀ of viral samples were combined (50 μl of each) and the

mixture was incubated at 37°C for 1 hour. The virus-serum mixtures (total 200 μl) were then inoculated on 70%-confluent rhabdomyosarcoma cells in a 96-well plate and monitored for the development of characteristic cytopathic effects for 4 days. The neutralizing titer of a particular serum and virus was defined as the reciprocal of 100% of the highest dilution that resulted in no observable cytopathic effect.

A.



B.




Figure 2 Neutralizing antibody titers in HFMD patients by microneutralization assay against EV71. A. HFMD patients were classified by dates of onset of illness. B. Serum samples of HFMD patients taken one day after symptoms of illness appeared had significantly higher antibody titers than control subjects ($p < 0.05$).

The EV71 FY573 isolate (subgenotype C4a, GenBank accession number: HM064456.1) used in this study was isolated from a patient with HFMD from Fuyang city of Anhui province in 2008.

Statistics

GraphPad Prism 5 was used in statistic analysis and graph preparations. P-values were calculated by student T-test.

Discussion

Studies of animal models revealed that antibody response plays a critical role in protection from EV71 infection [12-16]. Several seroepidemiological studies in humans have revealed that seroprevalence of EV71 antibodies increase with age [10,23,24], which supports the idea that increased humoral immunity may prevent adults from EV71 infection. Thus, it is of importance to know how humans respond to EV71 infection and to

what degree humoral immune responses play a role in EV71 infection. We found that 23.7% of HFMD patients had $\geq 1:128$ antibody titers, but none of the healthy children did. In addition, we found that 80% (4/5) of patients had neutralizing antibody titers against EV71 above 1:16 one day after the onset of illness. Two days after symptoms appeared, patients already had a level of neutralizing antibodies (GMT = 79.5) comparable to that of adults. In other words, humoral immune response was already elicited when clinical symptoms appeared. Interestingly, our data is in accordance with a previous report showing that neutralizing antibody levels are not correlated with HFMD severity [25]. However, this current study was a retrospective investigation and we only had a very small number of cases at early stages of infection. Whether the neutralizing antibody responses in patients to EV71 at early stages of infection correlate to the clinical severity of the disease remains to be determined by future investigations.

Previously Gomes et al. showed that only 40.8% of HFMD patients less than 3 years old had levels of neutralizing antibody $\geq 1:8$ [26]. Their results are not consistent with the results in this study or with the results reported by Chang et al [25]. This discrepancy may result from technical problems by using different EV71 isolates. They used classic EV71 strains (BrCr) but not a contemporary circulating EV71 isolate. In addition, the pathogens causing HFMD in the Brazilian study may not be only EV71 since they did not specify in the study.

Recently, a clinical trial for an EV71 vaccine has been officially approved in China (<http://clinicaltrials.gov/ct2/show/NCT01267903>). While there has been no clinical trial thus far for the EV71 vaccine, it is imperative to know what level of neutralizing antibody should be achieved in children after EV71 vaccination and the importance of cellular immunity in protection from EV71 infection. Adults are rarely infected with EV71 [27], thus they appear to have immunity against EV71 infection. Only 83.3% of healthy adults in this study were antibody-positive to EV71 ($\geq 1:8$ antibody titer). Even HFMD patients were not all positive (93.2%). In addition, 18.7% of HFMD patients did not have antibody titers $\geq 1:16$. Furthermore, similar to a previous study by Chang et al., we found that there was no correlation between the severity of the disease and neutralizing antibody levels. Thus, one may wonder, other than neutralizing antibodies, additional immune mechanisms may also contribute to the immunity against EV71 infection in humans.

Interestingly, both human leukocyte antigen serotypes, HLA-A33 (class I) and HLA-DR17 (class II), are significantly associated with EV71 infection, suggesting cellular immune responses may play an important role in human immunity against EV71 infection [28]. In

addition, a previous study found that the most severe EV71 cases, characterized by with pulmonary edema, had lower cellular antigen-specific Th1 cytokines coupled with a lower lymphocyte proliferation response to EV71 antigen in comparison to milder cases, which suggests that cellular immune responses are correlated to the clinical severity of HFMD [25]. Thus, induction of both humoral and cellular immunity should be considered in vaccine development and further analyzed by clinical trials.

List of abbreviations

EV71: Enterovirus 71; HFMD: Hand, foot and mouth disease; GMT: geometric mean titer; TCID: tissue culture infectious dose.

Acknowledgements

We wish to thank the healthcare workers from the Fuyang CDC for their generous support and cooperation. We also wish to thank Dr. Nevine El Khatib and the International Science Editing for their excellent editorial contribution. This work was supported by grants from the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-204) and 100 Talent Program of CAS.

Author details

¹Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 225 South Chongqing Road, Shanghai, 200025, P.R. China. ²Center for Disease Control of Fuyang city, 19 Zhongnan Avenue, Fuyang City, Anhui Province, 236300, P.R. China.

Authors' contributions

CY performed the experiments. LZ and JW performed the field study. CY and LQ designed the study, analyzed the data and wrote this manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 3 May 2011 Accepted: 16 June 2011 Published: 16 June 2011

References

1. Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, et al: Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. *Arch Virol* 1979, **60**:329-340.
2. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I: Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. *Arch Virol* 1982, **71**:217-227.
3. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, et al: Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. *Clin Infect Dis* 2000, **31**:678-683.
4. Chong CY, Chan KP, Shah VA, Ng WY, Lau G, Teo TE, Lai SH, Ling AE: Hand, foot and mouth disease in Singapore: a comparison of fatal and non-fatal cases. *Acta Paediatr* 2003, **92**:1163-1169.
5. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR: An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. *N Engl J Med* 1999, **341**:929-935.
6. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O: Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. *Microbiol Immunol* 2002, **46**:621-627.
7. Jee YM, Cheon DS, Kim K, Cho JH, Chung YS, Lee J, Lee SH, Park KS, Lee JH, Kim EC, et al: Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. *Arch Virol* 2003, **148**:1735-1746.

8. Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, How OM, Cardoso MJ, McMinn PC: **Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005.** *Emerg Infect Dis* 2007, **13**:1733-1741.
9. Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, et al: **An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China.** *J Clin Virol* 2009, **44**:262-267.
10. Zhu Z, Zhu S, Guo X, Wang J, Wang D, Yan D, Tan X, Tang L, Zhu H, Yang Z, et al: **Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated widely in central and southern China before large-scale outbreaks from 2008.** *Virology* 2010, **7**:300.
11. Wang LC, Tang SQ, Li YM, Zhao HL, Dong CH, Cui PF, Ma SH, Liao Y, Liu LD, Li QH: **A comparison of the biological characteristics of EV71 C4 subtypes from different epidemic strains.** *Virology* 2010, **25**:98-106.
12. Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM: **Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection.** *Vaccine* 2008, **26**:2882-2889.
13. Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC: **Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield.** *Vaccine* 2010, **28**:6951-6957.
14. Ong KC, Devi S, Cardoso MJ, Wong KT: **Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease.** *J Virol* 2010, **84**:661-665.
15. Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S: **EV71: an emerging infectious disease vaccine target in the Far East?** *Vaccine* 2010, **28**:3516-3521.
16. Zhang D, Lu J: **Enterovirus 71 vaccine: close but still far.** *Int J Infect Dis* 2010, **14**:e739-743.
17. Arita M, Shimizu H, Nagata N, Ami Y, Suzuki Y, Sata T, Iwasaki T, Miyamura T: **Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys.** *J Gen Virol* 2005, **86**:1391-1401.
18. WHO: **Report on the Hand, Foot and Mouth Disease Outbreak in Fuyang City, Anhui Province and the Prevention and Control in China.** 2008, 1-25.
19. Wang SM, Lei HY, Huang MC, Wu JM, Chen CT, Wang JN, Wang JR, Liu CC: **Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema.** *Pediatr Pulmonol* 2005, **39**:219-223.
20. Ooi EE, Phoon MC, Ishak B, Chan SH: **Seroepidemiology of human enterovirus 71, Singapore.** *Emerg Infect Dis* 2002, **8**:995-997.
21. Cao R, Han J, Deng Y, Yu M, Qin E, Qin C: **Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors.** *Clin Infect Dis* 2010, **50**:125-126.
22. Huang ML, Chiang PS, Luo ST, Liou GY, Lee MS: **Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71.** *J Virol Methods* 2010, **165**:42-45.
23. Diedrich S, Weinbrecht A, Schreiber E: **Seroprevalence and molecular epidemiology of enterovirus 71 in Germany.** *Arch Virol* 2009, **154**:1139-1142.
24. Rabenau HF, Richter M, Doerr HW: **Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany.** *Med Microbiol Immunol* 2010, **199**:45-51.
25. Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, Chiang YP, Chiang BL, Lee CY, Huang LM: **Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71.** *Pediatr Res* 2006, **60**:466-471.
26. Gomes Mde L, de Castro CM, Oliveira MJ, da Silva EE: **Neutralizing antibodies to enterovirus 71 in Belem, Brazil.** *Mem Inst Oswaldo Cruz* 2002, **97**:47-49.
27. Hamaguchi T, Fujisawa H, Sakai K, Okino S, Kurosaki N, Nishimura Y, Shimizu H, Yamada M: **Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult.** *Emerg Infect Dis* 2008, **14**:828-830.
28. Chang LY, Chang IS, Chen WJ, Huang YC, Chen GW, Shih SR, Juang JL, Shih HM, Hsiung CA, Lin TY, Huang LM: **HLA-A33 is associated with susceptibility to enterovirus 71 infection.** *Pediatrics* 2008, **122**:1271-1276.

doi:10.1186/1743-422X-8-306

Cite this article as: Yang et al.: Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. *Virology Journal* 2011 **8**:306.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

